| Detected | Trial | Change |
|---|---|---|
| 2026-06-03 | NCT06772623 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… |
Trial sites expanded: 92 -> 96 locations |
| 2026-05-28 | NCT06772623 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… |
Trial sites expanded: 85 -> 91 locations |
| 2026-05-20 | NCT07241039 A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711… |
Trial sites expanded: 9 -> 12 locations |
| 2026-05-19 | NCT06772623 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… |
Trial sites expanded: 64 -> 79 locations |
| 2026-05-14 | NCT06772623 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… |
Trial sites reduced: 74 -> 64 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2/3 | |||
| NCT06236438 | Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With… | Non-Small Cell Lung Cancer | Recruiting |
| Phase 2 | |||
| NCT06628310 | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV)… | Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma | Recruiting |
| Phase 1/2 | |||
| NCT06772623 | Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… | Non Small Cell Lung Carcinoma | Recruiting |
| Phase 1 | |||
| NCT05005403 | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small… | Non-Small Cell Lung Cancer | Recruiting |
| NCT07241039 | A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711… | Advanced Squamous Tumors | Recruiting |
| NCT02988960 | A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid… | Advanced Solid Tumors Cancer | Active, Not Recruiting |
| NCT05599984 | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves… | Advanced Solid Tumors | Active, Not Recruiting |